Evidence map›Paper›PMID 37171372›Full record

ArticleJournal of chemical information and modeling2023

Exploring the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry.

Po-Yu Kao, Ya-Chu Yang, Wei-Yin Chiang, Jen-Yueh Hsiao, Yudong Cao, Alex Aliper, Feng Ren, Alán Aspuru-Guzik, Alex Zhavoronkov, Min-Hsiu Hsieh and 1 more

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Multimodal Transformers and Their Applications in Drug Target Discovery for Aging and Age-Related Diseases.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Open-Source Machine Learning in Computational Chemistry.Journal of chemical information and modeling · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Po-Yu KaoInsilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.ORCID 0000-0002-9439-8819
Ya-Chu YangInsilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.
Wei-Yin ChiangHon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.
Jen-Yueh HsiaoHon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.
Yudong CaoZapata Computing, Inc., Boston, Massachusetts 02110, United States.
Alex AliperInsilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.
Feng RenInsilico Medicine Shanghai Ltd., Shanghai 201203, China.
Alán Aspuru-GuzikDepartment of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada.ORCID 0000-0002-8277-4434
Alex ZhavoronkovInsilico Medicine Hong Kong Ltd., Hong Kong SAR, 999077, China.
Min-Hsiu HsiehHon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.
Yen-Chu LinInsilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.

Indexed as

Artificial IntelligenceNeural Networks, ComputerComputing MethodologiesHumansPharmaceutical PreparationsQuantum TheoryPharmaceutical Preparations

Identifiers

PMID37171372
PMCPMC10268960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.